[HTML][HTML] Proteomics technologies for cancer liquid biopsies

Z Ding, N Wang, N Ji, ZS Chen - Molecular Cancer, 2022 - Springer
Alterations in DNAs could not reveal what happened in proteins. The accumulated
alterations of DNAs would change the manifestation of proteins. Therefore, as is the case in …

Progress and prospects of early detection in lung cancer

S Blandin Knight, PA Crosbie, H Balata… - Open …, 2017 - royalsocietypublishing.org
Lung cancer is the leading cause of cancer-related death in the world. It is broadly divided
into small cell (SCLC, approx. 15% cases) and non-small cell lung cancer (NSCLC, approx …

[HTML][HTML] Biomarkers in lung cancer screening: achievements, promises, and challenges

LM Seijo, N Peled, D Ajona, M Boeri, JK Field… - Journal of Thoracic …, 2019 - Elsevier
The present review is an update of the research and development efforts regarding the use
of molecular biomarkers in the lung cancer screening setting. The two main unmet clinical …

[HTML][HTML] British Thoracic Society guidelines for the investigation and management of pulmonary nodules: accredited by NICE

MEJ Callister, DR Baldwin, AR Akram, S Barnard… - Thorax, 2015 - thorax.bmj.com
This guideline is based on a comprehensive review of the literature on pulmonary nodules
and expert opinion. Although the management pathway for the majority of nodules detected …

[HTML][HTML] Liquid biopsy for lung cancer: up-to-date and perspectives for screening programs

GMS Casagrande, MO Silva, RM Reis… - International Journal of …, 2023 - mdpi.com
Lung cancer is the deadliest cancer worldwide. Tissue biopsy is currently employed for the
diagnosis and molecular stratification of lung cancer. Liquid biopsy is a minimally invasive …

Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study

G Sozzi, M Boeri, M Rossi, C Verri, P Suatoni… - Journal of clinical …, 2014 - ascopubs.org
Purpose Recent screening trial results indicate that low-dose computed tomography (LDCT)
reduces lung cancer mortality in high-risk patients. However, high false-positive rates, costs …

[HTML][HTML] Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics

H Padinharayil, J Varghese, MC John, GK Rajanikant… - Genes & …, 2023 - Elsevier
Continuous revision of the histologic and stage-wise classification of lung cancer by the
World Health Organization (WHO) provides the foundation for therapeutic advances by …

[HTML][HTML] Advances in lung cancer screening and early detection

C Li, H Wang, Y Jiang, W Fu, X Liu… - Cancer biology & …, 2022 - ncbi.nlm.nih.gov
Lung cancer is associated with a heavy cancer-related burden in terms of patients' physical
and mental health worldwide. Two randomized controlled trials, the US-National Lung …

[HTML][HTML] EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays

CJ Chapman, GF Healey, A Murray, P Boyle… - Tumor Biology, 2012 - Springer
Tumor-associated autoantibodies (AAbs) have been described in patients with lung cancer,
and the Early CDT®-Lung test that measures such AAbs is available as an aid for the early …

Autoantibodies: opportunities for early cancer detection

IK Macdonald, CB Parsy-Kowalska, CJ Chapman - Trends in cancer, 2017 - cell.com
Cancer cells can induce an immunological response resulting in the production of tumor-
associated (TA) autoantibodies. These serum immunobiomarkers have been detected for a …